Document is current
Any future updates will be listed below
-
Authors
Domínguez-González, Cristina
Madruga-Garrido, Marcos
Hirano, Michio
Martí, Itxaso
Martín, Miguel A.
Munell, Francina
Nascimento, Andrés
Olivé, Montse
Quan, Joanne
Sardina, M. Dolores
Martí, Ramon
Paradas, Carmen https://orcid.org/0000-0002-6917-2236
-
Funding
Funding for this research was provided by:
ern euro-nmd (PMP15_00025)
Zogenix Inc
- License Information
-
More Information
Article History
Received: 17 June 2021
Accepted: 18 September 2021
First Online: 2 October 2021
Declarations
:
: Not applicable.
: Not applicable.
: CP, CD-G, MM-G, IM, FM, AN, MAM, MO, MDS: No disclosures. MH: Paid consultant to Zogenix, Inc., and Entrada Therapeutics. These relationships are de minimus for Columbia University Irving Medical Center. Columbia University has a patent, which is licensed by Zogenix; this relationship is monitored by an unconflicted external academic researcher. Received honoraria from the AAN for speaking activities and research support from Zogenix and Entrada Therapeutics. JQ: Employment, ownership interest in Zogenix, Inc. RM: Paid consultant to Zogenix, Inc. This relationship is de minimus for Vall d’Hebron Research Institute (VHIR). VHIR has a patent, which is licensed by Zogenix; received Research support from Zogenix. RM, VHIR, and The Biomedical Network Research Centre on Rare Diseases (CIBERER) have filed patent applications covering potential use of deoxynucleoside treatment for POLG deficiency and other mtDNA replication defects in humans. VHIR and CIBERER have licensed pending patent applications related to these technologies to Zogenix, Inc., and VHIR and CIBERER may be eligible to receive payments related to development and commercialization of these technologies. Any potential licensing fees earned will be paid to VHIR and CIBERER and are shared with all inventors mentioned above, including RM, through VHIR and CIBERER policies on distribution and objectivity in research. In addition, “Carlos III, Institute of Health” and ERDF (FEDER), Ministry of Science and Innovation (Madrid, Spain), supported a Spanish collaborative grant (PMP15_00025) to MAM, RM, CP, MO, and FM regarding nucleoside personalized therapy, particularly in TK2-deficient patients. C. Paradas, M. Olivé, F. Munell, and A. Nascimento are members of the European Reference Network for Neuromuscular Diseases. M. Olivé is a member of XUECs (Xarxes d'Unitats d'Expertesa Clínica en Malalties Minoritàries).
